Valuation: Cosmos Holdings Inc.

Market Cap 12.66M 10.95M 10.23M 9.38M 17.65M 1.21B 17.93M 120M 47.1M 604M 47.55M 46.51M 2B P/E 2026 *
23.3x
P/E 2027 * 3.33x
Enterprise Value 12.66M 10.95M 10.23M 9.38M 17.65M 1.21B 17.93M 120M 47.1M 604M 47.55M 46.51M 2B EV / Sales 2026 *
0.15x
EV / Sales 2027 * 0.11x
Free-Float
63.51%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 60 26/02/2016
Director of Finance/CFO 43 11/11/2020
Chief Operating Officer 56 01/02/2023
Director TitleAgeSince
Director/Board Member 58 13/01/2014
Chairman 60 26/02/2016
Director/Board Member 59 18/11/2016
Change 5-day change 1-year change 3-year change Capi.($)
-5.65%-2.45% - - 12.66M
-0.21%+1.56%+30.06%+103.01% 101B
-0.53%+2.77%+50.18%+157.04% 55.37B
-0.67%-0.34%+4.59%+270.00% 24.21B
+1.64%-0.95%-12.47%-14.01% 8.29B
+4.21%-0.41%-31.74%-28.05% 7.53B
+0.59%-2.29%-9.93%-21.74% 6.75B
+0.34%+3.42%+19.47%+15.38% 6.19B
-0.55%-3.43%-4.67%+20.61% 5.07B
+0.81%-3.11%-6.73%-7.85% 3.69B
Average -0.00%-0.35%+4.31%+54.93% 24.28B
Weighted average by Cap. -0.07%+1.38%+25.63%+116.13%

Financials

2026 *2027 *
Net sales 84.3M 72.92M 68.1M 62.47M 117M 8.02B 119M 799M 314M 4.02B 317M 310M 13.29B 111M 95.84M 89.5M 82.11M 154M 10.55B 157M 1.05B 412M 5.29B 416M 407M 17.47B
Net income - -
Net Debt - -
Logo Cosmos Holdings Inc.
Cosmos Health Inc. is a diversified, vertically integrated global healthcare company. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe, C-Sept and C-Scrub. Through its subsidiary Cana Laboratories S.A., it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. It also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and over-the-counter (OTC) medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the United Kingdom. It also has research and development (R&D) partnerships targeting health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of patented nutraceuticals, specialized root extracts, proprietary complex generics, and OTC products.
Employees
-

Quarterly revenue - Rate of surprise